Prostate Cancer Drug Discoveries: What the Future Holds

Published by: Espicom Healthcare Intelligence

Published: Nov. 5, 2009 - 160 Pages

Table of Contents

EXECUTIVE SUMMARY

WHAT IS PROSTATE CANCER AND HOW DOES IT AFFECT PATIENTS?

Screening

Risk Factors

Stages of the Disease

PATIENT STATISTICS

Incidence, Mortality and Survival

PATIENT MODEL

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

CURRENT TREATMENTS

Watchful Waiting/Active Monitoring

Surgery

Radiotherapy

Hormone Therapy

Chemotherapy

THE CURRENT PROSTATE CANCER MARKET

PLAYERS AND PRODUCTS IN 2008

Geographic Areas

RESEARCH & DEVELOPMENT OF PROSTATE CANCER DRUGS

WHAT THE FUTURE HOLDS

GLOBAL SALES FORECASTS TO 2015

Model Assumptions

PLAYERS AND PRODUCTS IN 2015

COMPETITOR RATIO ANALYSIS

Competitor Ratio Analysis Criteria

COMPETITOR RATIO ANALYSIS - PRODUCTS

COMPETITOR RATIO ANALYSIS - COMPANIES

Winners and Losers

Winners

Losers

Winners/Losers

ANALYSIS OF LEADING BRANDS

Current Products’ Patent Exposure

LHRH Analogues

Eligard

Lupron/Lupron Depot

Zoladex

LHRH Antagonist

Firmagon

Anti-Androgens

Casodex

Chemotherapy

Taxotere

ANALYSIS OF PHASE III DRUGS

Chemotherapy

Cabazitaxel

Orplatna

Angiogenesis Inhibitors

Aflibercept

Avastin

Sprycel

Sutent

Hormone Therapy

Abiraterone

Acapodene

Avodart

MDV3100

Immunotherapy

Ipilimumab

Provenge

Selective Endothelial Receptor Antagonists

Xinlay

ZD4054

ANALYSIS OF PHASE II DRUGS

ASA404

AT-101

OGX-011

Onyvax-P

PROSTVAC

TASQ

Panobinostat

DISCONTINUATION OF DRUGS

APPENDIX 1

APPENDIX 2

PCA Tumour Grading System - Gleason Score

APPENDIX 3

Phase Transition Probability

GLOSSARY

REFERENCES

ACRONYMS

Index of Charts

Number of New UK Prostate Cancer Cases and Age-Specific Incidence Rates, 2006

International Variation in Prostate Cancer Incidence Rates

US Male Age-Adjusted Prostate Cancer Incidence Rates by Race/Ethnicity (1992-2006)

Projected % Change in Age-Standardised Prostate Cancer Mortality in the US, Europe and Japan, 2002-2015

Incidence and Mortality Rates of Prostate Cancer in Selected Countries

Estimated US Cancer Cases, 2009

Estimated US Cancer Deaths, 2009

Prostate Cancer Incidence, Top Seven Countries (2008-2015)

Prostate Cancer Mortality, Top Seven Countries (2008-2015)

Therapy Sales Split for Major Prostate Cancer Products, 2008

Market Share for Major Branded Prostate Cancer Drugs, 2008

Market Share of Major Prostate Cancer Players by Sales, 2008

US Prostate Cancer Branded Drugs Sales Split, 2008

Sales Forecasts of Current Leading PCA Drugs (US$ millions)

Sales Forecasts of Future Leading PCA Drugs (US$ millions)

Therapy Sales Split for Major Prostate Cancer Products, 2015

Global Market Share of Prostate Cancer Players by Sales (Dec 2015E)

Competitor Ratio Analysis Scores by Product

Current Major Prostate Cancer Products

Major Prostate Cancer Products, 2015

Combined Company Competitor Ratio Analysis Scores

Eligard Prostate Cancer Sales (2008A-2015E)

Lupron Prostate Cancer Sales (2008E-2015E)

Zoladex Prostate Cancer Sales (2008E-2015E)

Firmagon Prostate Cancer Sales (2009E-2015E)

Casodex Prostate Cancer Sales (2008A-2015E)

Taxotere Prostate Cancer Sales (2008A-20015E)

Cabazitaxel Prostate Cancer Sales (2011E-2015E)

Angiogenesis is the Formation of New Blood Vessels

Agents Targeting the VEGF Pathway

Aflibercept Prostate Cancer Sales (2013E-2015E)

Avastin Prostate Cancer Sales (2012E-2015E)

Sprycel Prostate Cancer Sales (2014E-2015E)

Sutent Prostate Cancer Sales (2012E-2015E)

Mode of Action of Abiraterone

Abiraterone Prostate Cancer Sales (2013E-2015E)

Acapodene Prostate Cancer Sales (2011E-1015E)

Avodart Prostate Cancer Sales (2010E-2015E)

Schematic of MDX-010’s Mechanism of Action

Ipilimumab Prostate Cancer Sales (2014E-2015E)

Schematic of Provenge’s Mechanism of Action

Provenge Prostate Cancer Sales (2010E-2015E)

Phase II EPOC Study Results

ZD4054 Prostate Cancer Sales (2012E-2015E)

ASA404 Mechanism of Action

ASA404 Phase II Results

Ascenta AT-101 Pipeline

OGX-011 Phase II Measurable Disease Response

OGX-011 Phase II Conclusions

TASQ Phase Ib Efficacy in HRPCA

Panobinostat Mechanism of Action

TNM Staging System for Prostate Cancer

Gleason Grading System

Index of Tables

Worldwide Prostate Cancer Population Model (2008-2015)

Prostate Cancer Population Models, Top Seven Countries (2008-2015)

Drugs in Development to Treat Prostate Cancer

Timeline of Selected PCA Development Projects

Sales Forecasts of Current and Future Leading PCA Drugs (US$ millions)

Key Prostate Cancer Drugs Analysed

Summary of Key Companies and Drugs in the PCA Market by 2015

Comparison of Leading PCA Agents

Patent Exposure of Leading Brands

Major Phase III Development Candidates for PCA

Proposed Filings of New Indications for Avastin

Selected Phase II PCA Development Candidates

Drugs Discontinued from Clinical Development in PCA

Probability of Launch

Abstract

Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about market developments in this chapter of Cancer Drug Discoveries.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.